Total Voting Rights
November 05 2010 - 11:37AM
UK Regulatory
TIDMHIK
RNS Number : 7318V
Hikma Pharmaceuticals Plc
05 November 2010
Hikma Pharmaceuticals PLC - Voting Rights and Capital
LONDON, 5 November 2010 Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)
notifies the market that as at 31 October 2010 its capital consists of
193,401,389 ordinary shares with voting rights. There are no shares held in
treasury.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under
the FSA's Disclosure and Transparency Rules.
- ENDS -
Enquiries:
+---------------------------+------------------------------+
| Hikma Pharmaceuticals PLC | |
+---------------------------+------------------------------+
| Henry Knowles | +44 20 7399 2760 |
| Company Secretary | |
| | |
+---------------------------+------------------------------+
| | |
+---------------------------+------------------------------+
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed products. Hikma's operations are conducted
through three businesses: "Branded", "Injectables" and "Generics" based
principally in the Middle East and North Africa ("MENA") region, where it is a
market leader, the United States and Europe. In 2009, Hikma achieved revenues
of $637 million and profit attributable to shareholders of $78 million. For
news and other information, please visit www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREASFSEDXEFFF
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024